Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study of XL784 Administered Orally to Subjects With Albuminuria Due to Diabetic Nephropathy

NCT00312780 is registered in ClinicalTrials.gov with Symphony Evolution, Inc. as lead sponsor.

NCT NCT00312780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00312780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study of XL784 Administered Orally to Subjects With Albuminuria Due to Diabetic Nephropathy
Lead sponsor
Symphony Evolution, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2006
Completion date
December 31, 2007
Enrollment
125 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

albuminuria, diabetic nephropathy